Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Dermatology
    • Refractory urticaria-...

    Refractory urticaria- new treatment with Omalizumab

    Written by Anjali Nimesh Nimesh Published On 2018-04-01T19:30:02+05:30  |  Updated On 1 April 2018 7:30 PM IST
    Refractory urticaria- new treatment with Omalizumab


    Chronic spontaneous urticaria (CSU) is defined as the occurrence of wheels or angioedema or both occurring on most of the days in a week and lasting for more than 6 weeks, without any identifiable triggers. It is a common problem with a lifetime prevalence of 7.8–22.3%.The current guidelines recommend the use of nonsedating H1 antihistaminics as the first-line therapy. The dosage of antihistaminics can be increased up to four times the licensed recommendations in case of no response to the second-line treatment. Omalizumab, cyclosporine, and montelukast form the third line of treatment in patients who do not respond to second-line treatment.

    Dr.Shekhar Neema at Command Hospital, Kolkata, West Bengal, India, and colleagues conducted a study to evaluate the effects of omalizumab in chronic spontaneous urticaria in Indian patients.The study was conducted in a tertiary care center and it was retrospective and descriptive in nature.The researchers have found that Omalizumab could be used in patients after failure of third-line therapies.The study has been published in the Indian Journal of Dermatology.



    Omalizumab is safe and effective for the treatment of patients with refractory chronic spontaneous urticaria (CSU) not responding to other third-line therapies such as an addition of montelukast and cyclosporine. The study also reports that omalizumab may achieve lasting remission in one-fourth of the patients with refractory CSU.

    Researchers analyzed 24 patients with CSU who failed to respond to updosing of antihistamines and cyclosporine. All patients were administered omalizumab injection 300 mg/month and followed up for 6 months after the last 3 injections. Response to therapy (remission, complete response, partial response, and no response) was recorded using urticaria activity score (UAS) and urticaria control test (UCT).


    Of 24 patients, 96% showed the complete response to treatment within 1 week of initiation of the treatment. Complete remission was seen in 25% of patients followed by the satisfactory response in 50% and partial response in 20.83%. Average UAS over 7 days was reduced from 24.4 to 4 after 2 weeks of the treatment initiation with omalizumab, and most of the patients experienced complete relief from symptoms on the fourth and fifth day of the treatment. Average UCT scores improved from 6 to 14 in patients treated with omalizumab. None of the patients reported injection site reaction or anaphylaxis with omalizumab.


    The authors concluded that Omalizumab is a safe and effective treatment for the management of chronic spontaneous urticaria. It can be used in Indian setting after failure to other third-line therapies such as the addition of montelukast and cyclosporine due to a high cost of treatment.“Our finding was similar with results from 3 pivotal studies on omalizumab (GLACIAL, ASTERIA I, and ASTERIA II), which observed that omalizumab 300 mg/month was effective irrespective of background therapy,” the authors said.


    For more details click on the link : doi: 10.4103/ijd.IJD_342_16
    chronic spontaneous urticariacyclosporineDr Shekhar NeemaIndian Journal of DermatologyinjectionsomalizumabTherapiesurticaria activity scoreurticaria control test
    Source : with inputs Indian Journal of Dermatology

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Anjali Nimesh Nimesh
    Anjali Nimesh Nimesh
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok